Back

Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

26 August 2017 (15:35 - 15:50)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited) Lipids ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail
Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.
Doctor M. Farnier (Dijon, FR)
Presentation thumbnail
PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?
Doctor G. Hovingh (Amsterdam, NL)
Presentation thumbnail
PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.
Professor P. Sever (London, GB)
Presentation thumbnail
Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.
Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

The Event

Event poster

ESC Congress 2017

26 August 2017 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources